Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?Roberto Latagliata, Robin Foà, Daniela De Benedittis et al.|European Journal Of Haematology|2018Cited by 6
A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trialChiara Sartor, Antonio Curti, Anna Candoni et al.|Blood|2025Cited by 0